Comparative clinical and economic evaluation of polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisolone (R-CHP) in the 1^st line therapy for adult patients with diffuse large B-cell lymphoma

Aim. To assess the pharmacoeconomic feasibility of using polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisolone (R-CHP) in 1^st line therapy of adult patients with diffuse large B-cell lymphoma in the Russian healthcare system, taking into account the currently used therapeutic practices in oncohematology.
Materials and methods. The design of the study is a retrospective analysis of literature data. Clinical and economic analysis (incremental cost–effectiveness analysis, case-based approach) was performed using sensitivity assessment. The sources of data on the effectiveness of the analyzed drugs were publications on clinical trials, on the cost of drugs – the state register of maximum selling prices, data from the manufacturer.
Results. An incremental cost–effectiveness analysis was performed using a case-based approach comparing the cost of progression-free life-year gained. Brentuximab vedotin, already included in the list of vital and essential drugs and provided at the expense of budgetary funds, was chosen as the reference drug. It has been established that the cost of progression-free life-year gained (ICER) with the use of polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisolone (R-CHP) in 1^st line therapy of adult patients with diffuse large B-cell lymphoma by 60.8 %, or 41.6 million rubles, lower than the cost of progression-free life-year gained when using brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine in the 1^st line therapy of patients with CD30-positive classical Hodgkin’s lymphoma. Sensitivity assessment showed the stability of the obtained results of clinical and economic analysis to changes in the cost of drugs in compared therapy regimens. The results were sensitive to changes in the efficacy of the compared regimens.
Conclusion. The obtained results of the clinical and economic analysis demonstrated that the use of polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisolone (R-CHP) in the 1^st line therapy of adult patients with diffuse large B-cell lymphoma in the Russian healthcare system is economically appropriate.

1. State of oncological care in Russia in 2019. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2020. 239 p. (In Russ.).

2. Armitage J.O., Weisenburger D.D. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 1998;16(8):2780–95. DOI:10.1200/JCO.1998.16.8.2780

3. Tilly H., Gomes da Silva M., Vitolo U. et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol 2015; 26(Suppl 5):v116–25. DOI:10.1093/annonc/mdv304

4. Суборцева И.Н. Клинико-биологические особенности первичной экстранодальной диффузной В-крупноклеточной лимфомы. Дис. … канд. мед. наук. М., 2012. Subortseva I.N. Clinical and biological features of primary extranodal diffuse large B-cell lymphoma. Dis. … candidate of medical sciences. Moscow, 2012. (In Russ.).

5. Ziepert M., Hasenclever D., Kuhnt E. et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28(14):2373–80. DOI:10.1200/JCO.2009.26.2493

6. Crump M., Neelapu S.S., Farooq U. et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017;130(16):1800–8. DOI:10.1182/blood-2017-03-769620

7. Kaplanov K.D., Volkov N.P., Klitochenko T.Yu. et al. Analysis of the regional register of patients with diffuse large B-cell lymphoma: risk factors and problems of immunochemotherapy. Klinicheskaya onkogematologiya = Clinical Oncohematology 2019;12(2):154–64. (In Russ.). DOI:10.21320/2500-2139-201912-2-154-164

8. Nagle S.J., Woo K., Schuster S.J. et al. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. Am J Hematol 2013;88(10):890–4. DOI:10.1002/ajh.23524

9. Aggressive non-follicular lymphomas ‒ diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, Burkitt’s lymphoma. Clinical guidelines. Ministry of Health of the Russian Federation. Moscow, 2020. (In Russ.).

10. Instructions for medical use of the drug Polivy (polatuzumab vedotin). Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=de777901-accd-494c-aea9-18752c979552&t=. (In Russ.).

11. https://www.roche.com/media/releases/med-cor-2019-06-11b.htm.

12. Challenges in the Treatment of Primary Refractory and Relapsed Diffuse Large B-cell Lymphoma in the Russian Federation. What will the future hold? Resolution of the advisory board. Klinicheskaya onkogematologiya = Clinical Oncohematology 2020;13(1):112–4. (In Russ.).

13. Decree of the Government of the Russian Federation No. 871 dated 28.08.2014 (as amended on 03.12.2020) “On Approval of the Rules for the Formation of the Lists of Medicinal Products for Medical Use and the Minimum Range of Medicinal Products Necessary for the Provision of Medical Assistance”. (In Russ.).

14. Decree of the Government of the Russian Federation No. 2021 dated 03.12.2020 “On Amendments to the Rules for the Formation of the Lists of Medicinal Products for Medical Use and the Minimum Range of Medicinal Products Necessary for the Provision of Medical Assistance”. (In Russ.).

15. Instructions for medical use of the drug Adcetris (brentuximab vedotin). Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=69cf0e90-4faf-4e84-8295-d457a1c5e4ed&t=. (In Russ.).

16. https://www.ncbi.nlm.nih.gov/pubmed.

17. Tilly H., Morschhauser F., Sehn L.H. et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022;386(4):351–63. DOI:10.1056/NEJMoa2115304

18. Straus D.J., Długosz-Danecka M., Connors J.M. et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol 2021;8(6):e410–21. DOI:10.1016/S23523026(21)00102-2. Erratum in: Lancet Haematol 2022;9(2):e91.

19. https://grls.rosminzdrav.ru/pricelims.aspx (date of the application 25.12.2022). (In Russ.).

20. Tariff agreement for payment for medical care provided under the territorial program of compulsory medical insurance of Moscow for 2022. Moscow, 2021. (In Russ.).